EUVIMEDEUVIMED entdecken
Crossref

Does COVID-19 infection or COVID-19 mRNA vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss?

Toshiyuki Takeshita, Naomi Nishimiya, Yachika Hihara

Journal of Reproductive Immunology · 2025

DOI: 10.1016/j.jri.2025.104442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Reproductive Immunology, 2025. Verfasst von Toshiyuki Takeshita und 2 weiteren Autor:innen. Beteiligte Einrichtung: Takeshita Ladies Clinic, 13-7 Samon-cho, Shinjuku-ku, Tokyo 160-0017, Japan. Electronic address: toshimac@nms.ac.jp. Hauptthemen laut MEDLINE: Abortion, Habitual, Antibodies, Antiphospholipid, COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is a well-established cause of recurrent pregnancy loss (RPL). If coronavirus disease 2019 (COVID-19) infection or vaccination induces antiphospholipid antibody (aPL) production, it may lead to miscarriage in subsequent pregnancies. We investigated the association between COVID-19 infection and vaccination history with aPL positivity in women with RPL. This study included 424 women with RPL. We found no difference in the positivity rate for aPL according to the presence or absence of a history of COVID-19 infection. The positivity rate was significantly higher in patients infected during the omicron period (27.9 %, 43/154) than in those infected during the delta period (8.7 %, 2/23) of the COVID-19 pandemic (P = 0.0351). Of the 416 patients with a detailed vaccination history, 365 (87.7 %) had received at least one vaccination. The aPL positivity rate did not significantly differ according to the history of vaccination or number of vaccinations. Our results suggest that mild COVID-19 infection and vaccination are unlikely to stimulate aPL production and, therefore, are unlikely to increase miscarriage due to APS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortion, HabitualAntibodies, AntiphospholipidCOVID-19SARS-CoV-2COVID-19 VaccinesAntiphospholipid SyndromeHumansFemaleAdultPregnancyVaccination

Stichwörter der Autor:innen

Antiphospholipid antibodiesAntiphospholipid syndromeCoronavirus disease 2019Recurrent pregnancy lossVaccine

Substanzen

Antibodies, AntiphospholipidCOVID-19 Vaccines

Autor:innen und Institutionen

  • Takeshita Ladies Clinic, 13-7 Samon-cho, Shinjuku-ku, Tokyo 160-0017, Japan. Electronic address: toshimac@nms.ac.jp.
  • Takeshita Ladies Clinic, 13-7 Samon-cho, Shinjuku-ku, Tokyo 160-0017, Japan. Electronic address: tlcnurse0@gmail.com.
  • Takeshita Ladies Clinic, 13-7 Samon-cho, Shinjuku-ku, Tokyo 160-0017, Japan. Electronic address: tlc.takeshita@gmail.com.

Zitieren

APA

Takeshita, T., Nishimiya, N., & Hihara, Y. (2025). Does COVID-19 infection or COVID-19 mRNA vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss?. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2025.104442

Vancouver

Takeshita T, Nishimiya N, Hihara Y. Does COVID-19 infection or COVID-19 mRNA vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss?. Journal of Reproductive Immunology. 2025. doi:10.1016/j.jri.2025.104442

BibTeX
@article{Takeshita2025,
  author = {Takeshita, Toshiyuki and Nishimiya, Naomi and Hihara, Yachika},
  title = {Does COVID-19 infection or COVID-19 mRNA vaccination induce antiphospholipid antibodies in women with recurrent pregnancy loss?},
  journal = {Journal of Reproductive Immunology},
  year = {2025},
  doi = {10.1016/j.jri.2025.104442}
}
Kostenlos starten →